[go: up one dir, main page]

CY1106638T1 - Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3 - Google Patents

Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3

Info

Publication number
CY1106638T1
CY1106638T1 CY20071100741T CY071100741T CY1106638T1 CY 1106638 T1 CY1106638 T1 CY 1106638T1 CY 20071100741 T CY20071100741 T CY 20071100741T CY 071100741 T CY071100741 T CY 071100741T CY 1106638 T1 CY1106638 T1 CY 1106638T1
Authority
CY
Cyprus
Prior art keywords
dihydroxyvitamin
oxime
hypercalcemium
1alpha
low
Prior art date
Application number
CY20071100741T
Other languages
English (en)
Inventor
Gary H. Posner
Jay A. White
Glenville Jones
Bethany Halford
Mehmet Kahraman
Heung Bae Jeon
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CY1106638T1 publication Critical patent/CY1106638T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει νέα 16-ενο-C25-οξίμης και 16-ενο-C-25-οξίμης αιθερο ανάλογα της 1α,25-διϋδρόξυ βιταμίνης D3, συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις και μεθόδους χρήσης αυτών των ενώσεων σαν αναστολείς της CYP24. Συγκεκριμένα, η ένωση του Τύπου I είναι χρήσιμη για θεραπεία ασθενειών, οι οποίες ευεργετούνται από ρύθμιση των επιπέδων της 1α,25-διϋδρόξυ βιταμίνης D3, για παράδειγμα, κυτταρο-πολλαπλασιαστικών διαταραχών.
CY20071100741T 2001-10-12 2007-06-04 Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3 CY1106638T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32842801P 2001-10-12 2001-10-12
PCT/CA2002/001519 WO2003031400A1 (en) 2001-10-12 2002-10-11 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3

Publications (1)

Publication Number Publication Date
CY1106638T1 true CY1106638T1 (el) 2012-01-25

Family

ID=23280940

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100741T CY1106638T1 (el) 2001-10-12 2007-06-04 Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3

Country Status (11)

Country Link
US (1) US6982258B2 (el)
EP (1) EP1436257B1 (el)
JP (1) JP4436674B2 (el)
AT (1) ATE360000T1 (el)
CA (1) CA2463505C (el)
CY (1) CY1106638T1 (el)
DE (1) DE60219655T2 (el)
DK (1) DK1436257T3 (el)
ES (1) ES2283593T3 (el)
PT (1) PT1436257E (el)
WO (1) WO2003031400A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU2001278956B2 (en) 2000-07-18 2007-04-05 Genzyme Corporation Stabilized 1alpha-hydroxy vitamin d
US20050059641A1 (en) * 2003-06-17 2005-03-17 Aphios Corporation Compositions and methods for treating and preventing cancer using analogs of vitamin D
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
KR20070038460A (ko) * 2004-05-10 2007-04-10 노바세아, 인크. 활성 비타민 디(ｄ) 화합물을 이용한 동맥 재협착의 예방
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006074227A2 (en) * 2005-01-04 2006-07-13 Johns Hopkins University HIGHLY ANTIPROLIFERATIVE, LOW-CALCEMIC, ANALOGS OF THE HORMONE 1α, 25-DIHYDROXYVITAMIN D3 WITH CARBONYL SIDE CHAINS
CA2605815A1 (en) * 2005-04-25 2006-11-02 Cytochroma Inc. Low-calcemic 16,23-diene 25-oxime analogs of 1alpha,25-dihydroxy vitamin d3
CA2924200C (en) * 2005-10-12 2017-09-05 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
PT3357496T (pt) 2006-06-21 2020-05-12 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
JP2010524973A (ja) * 2007-04-18 2010-07-22 ジョンズ ホプキンス ユニバーシティ カルシトリオールの低カルシウム血性、高抗増殖性類似体
JP5444212B2 (ja) * 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド ビタミンｄ不足および欠乏症の治療方法
JP5647516B2 (ja) * 2007-04-25 2014-12-24 シトクロマ インコーポレイテッド ビタミンｄ療法のための方法および化合物
EP3335712B1 (en) 2007-04-25 2025-09-10 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
EP2762132A1 (en) 2007-04-25 2014-08-06 Cytochroma Inc. Controlled Release 25-Hydroxyvitamin D
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009120565A2 (en) 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
KR101852042B1 (ko) * 2008-04-02 2018-04-25 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
US20100227414A1 (en) * 2009-03-05 2010-09-09 Trex Enterprises Corp. Affinity capture mass spectroscopy with a porous silicon biosensor
JP5887672B2 (ja) * 2010-01-13 2016-03-16 シトクロマ インコーポレイテッド ビタミンｄ関連化合物の１−デオキシ類似体
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
US9884067B2 (en) 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
MX2016001901A (es) 2013-08-12 2016-10-13 Tokai Pharmaceuticals Inc Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104557647B (zh) * 2015-01-13 2016-07-06 南京理工大学 维生素d肟类衍生物、合成方法及其应用
CN104945296B (zh) * 2015-06-09 2016-08-24 南京理工大学 一类芳香醛腙修饰的维生素d2衍生物、合成及其应用
KR20230056790A (ko) 2016-03-28 2023-04-27 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
CN117003679A (zh) * 2022-04-29 2023-11-07 南澳大利亚大学 新型抑制剂化合物
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481198A (en) * 1984-02-13 1984-11-06 Wisconsin Alumni Research Foundation Vitamin D metabolism inhibitor
GB9623569D0 (en) * 1996-11-13 1997-01-08 Immunodiagnostic Systems Ltd Vitamin D immumoassay systems

Also Published As

Publication number Publication date
US6982258B2 (en) 2006-01-03
CA2463505A1 (en) 2003-04-17
JP2005536444A (ja) 2005-12-02
ATE360000T1 (de) 2007-05-15
DE60219655D1 (de) 2007-05-31
EP1436257B1 (en) 2007-04-18
PT1436257E (pt) 2007-05-31
CA2463505C (en) 2011-07-12
ES2283593T3 (es) 2007-11-01
US20030171342A1 (en) 2003-09-11
JP4436674B2 (ja) 2010-03-24
DE60219655T2 (de) 2007-12-27
DK1436257T3 (da) 2007-06-25
EP1436257A1 (en) 2004-07-14
WO2003031400A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
CY1106638T1 (el) Χαμηλα - υπερασβεστεμικα οξιμης αναλογα της 1αλφα, 25-διϋδροξυ βιταμινη d3
ATE543796T1 (de) 24-sulfoximine vitamin d3 derivate
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
HN1998000157A (es) Agonistas de prostaglandinas
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
BR9804437A (pt) Compostos para a osteoporose
UY27450A1 (es) Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
CY1114582T1 (el) Παραγωγα αλκυνυλιου ως ρυθμιστες μεταβολοτροπων υποδοχεων γλουταμινικου οξεος
NO331013B1 (no) Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
CY1107839T1 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
IS2564B (is) Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
NO20031687L (no) Veksthormonsekretagoger
NO20073801L (no) Atineoplastiske kombinasjoner
NO20050122L (no) Prodrug av eksitasjonsaminosyrer
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
BRPI0414868A (pt) composições e métodos compreendendo compostos relacionados com prostaglandina e peptìdios da famìlia do fator trifoliado para o tratamento de glaucoma com hiperemia reduzida
WO2004054968A3 (en) 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
EA200501584A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
ATE443044T1 (de) Tace inhibitoren
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları